Dose-response comparison of ipratropium bromide from a metered-dose inhaler and by jet nebulisation.

Gomm, S A; Keaney, N. P.; Hunt, Linda; Allen, Stephen; Stretton, T. B.

doi:10.1136/thx.38.4.297

Cited by 32 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Using measurements of large airways flow we have demonstrated that vagal activity to the bronchi can be blocked completely using intravenous atropine but not by nebulized ipratropium. A single large dose of ipratropium was used based on previous literature so as to keep the methodology of the study as simple as possible (Gomm et al, 1983;Jenkins et al, 1982). This dose would almost certainly block completely airway muscarinic receptors both at 04.00 h and 16.00 h (Catterall et al, 1988).…”

Section: Resultsmentioning

confidence: 99%

“…Before the subjects received either the active or the placebo arm, three sets of baseline measurements were performed separated by 10 min intervals. Peak expiratory flow rate (PEFR), specific airways conductance (sGaw) and pulse rate were measured 5 min after each intravenous injection and 1 h after nebulisation (Gomm et al, 1983;Jenkins, 1982). The best of three PEFRs and the average of sixteen panting loops for sGaw were used at each stage of the experiment except for the runin period when the best of nine PEFRs and the average of 48 panting loops were used.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

The effect of the circadian rhythm of vagal activity on bronchomotor tone in asthma.

Morrison

Pearson

1989

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 The effect of the diurnal activity of the parasympathetic nervous system on bronchomotor tone and heart rate was studied in seven asthmatics with nocturnal asthma using both intravenous atropine and nebulised ipratropium at 04.00 h and 16.00 h. 2 A diurnal variation in vagal activity was demonstrated with higher vagal activity occurring at night. 3 There was a strong correlation between the initial response of both airway calibre and heart rate to vagal block both at 04.00 h and 16.00 h. However the duration of bronchodilation after vagal block was greater than with the heart rate suggesting differing sensitivities of pulmonary and cardiac muscarinic receptors to anticholinergic antagonists. 4 The bronchodilation seen after ipratropium was less than that after atropine suggesting that the intravenous route is preferable to study the physiological effect of vagal block in vivo.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

The effect of the circadian rhythm of vagal activity on bronchomotor tone in asthma.

Morrison

Pearson

1989

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Авторы провели сравнительное исследование применения небулизационного раствора и ДАИ ипратропия бромида у пациентов преимущественно с бронхиальной астмой и установили, какая доза препарата необходима для получения 99% максимально достижимого бронходилататорного ответа на ипратропии. Для раствора, распыляемого при помощи небулайзера Wright, эта доза составляла 78 мкг и 82 мкг, когда применялся ДАИ [33].…”

Section: влияние различных средств доставки препаратов на клиническую эффективность бронходилататоровunclassified

The use of short-acting bronchodilators in patients with chronic bronchoobstructive pathology at the present stage

et al. 2021

View full text Add to dashboard Cite

Inhaled short-acting bronchodilators (beta-agonists and M-anticholinergics) have been used for a long time in patients with bronchoobstructive diseases, the main representatives of which are chronic obstructive pulmonary disease (COPD) and bronchial asthma (BA). Given the fact that most patients with COPD and BA are treated with long-acting bronchodilators, the question arises about the place of short-acting drugs in modern treatment algorithms for bronchoobstructive pathology. The data on how many patients take short-acting beta-agonists and M- anticholinergics in real-life clinical practice, and how appropriate it is to use these drugs on top of prolonged drugs are provided. The Russian part of the international POPE-study analyzed the characteristics of outpatients with COPD. It was found that the vast majority of patients have short-acting bronchodilators as part of their therapy, and more than 50% of patients receive a combination of SABA and SAAC, and in most cases this is represented by a combination of fenoterol + ipratropium. Taking into account that the majority of patients with COPD and asthma receive prolonged bronchodilators, important from a practical point of view is the question of the effectiveness of short-acting drugs on the background of prolonged ones. The article discusses these aspects of therapy and provides evidence that the use of SABA and SAAC provides an opportunity to achieve additional bronchodilatation when used against the background of prolonged bronchodilators. Thus, symptomatic use of SABA and SAAC on demand in bronchoobstructive pathology have sufficient justification even in the presence of a combination of prolonged bronchodilators in patient therapy. At the same time, it is necessary to take into account the increased probability of side effects with such drug regimen. The article also discusses the issues of different types of inhalation devices for short-acting bronchodilators (nebulizers and metered-dose aerosol inhalers), provides data on their comparative effectiveness and safety.

show abstract

“…[53][54][55] Twenty three studies in adults showed clinical equivalence for inhaler devices and nebulisers for the main pulmonary outcomes (FEV 1 and PEFR) and no evidence of significant difference in other outcomes. [56][57][58][59][60][61][62][63][64][65][66][67][68][69] Figure 5 shows the standardised mean difference of FEV 1 between nebulisers and hand held inhaler devices for the delivery of β agonists in stable asthma. 54 57-60 62 63 65-67 69-71 Updated searching identified two further studies.…”

Section: Effectiveness Of Nebulisersmentioning

confidence: 99%

Inhaler devices for the treatment of asthma and chronic obstructive airways disease (COPD)

Wright

Brocklebank²,

Ram³

2002

Quality and Safety in Health Care

View full text Add to dashboard Cite

Dose-response comparison of ipratropium bromide from a metered-dose inhaler and by jet nebulisation.

Abstract: The dose-response relationships of the anticholinergic bronchodilator drug ipratropium bromide were studied. Cumulative doses totalling 288

Cited by 32 publications

References 11 publications

The effect of the circadian rhythm of vagal activity on bronchomotor tone in asthma.

The effect of the circadian rhythm of vagal activity on bronchomotor tone in asthma.

The use of short-acting bronchodilators in patients with chronic bronchoobstructive pathology at the present stage

Inhaler devices for the treatment of asthma and chronic obstructive airways disease (COPD)

Contact Info

Product

Resources

About